Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This commentary notes that 5-alpha reductase inhibitors have successfully treated benign prostatic hyperplasia and androgenetic alopecia but reports no new findings.

BPH treatment improved with personalized medicine, new drugs, and less invasive surgeries.

This article reviews potential prevention and intervention strategies for prostate cancer, including 5alpha-reductase inhibition, but reports no new clinical findings.

This research highlights the shift from surgical to pharmacologic and less invasive treatments for benign prostatic hyperplasia, noting finasteride's effectiveness in men with enlarged prostates and its ability to reduce acute urinary retention risk compared to alpha-blockers.

This study reports two cases where localized prostate cancer with low PSA levels was incidentally detected through CT scans performed for other medical reasons.

This review discusses the use of antiandrogens like flutamide and its derivatives in prostate cancer treatment and highlights the need for next-generation antiandrogens for improved efficacy; it reports no new clinical results.

This study found that finasteride significantly reduced VEGF expression and microvessel density in prostatic suburethral tissue, suggesting a mechanism for decreased bleeding in patients with benign prostatic hyperplasia.

This review discusses phytotherapy options for managing benign prostatic hyperplasia, noting some herbal agents show promise in trials for mild-moderate symptoms but more evidence is needed for others.

This study identified LY191704 as a specific noncompetitive inhibitor of human 5 alpha-reductase type 1, which may be useful in treating endocrine disorders related to DHT overproduction.

This review examines various androgen deprivation therapy methods for advanced prostate cancer, highlighting benefits and potential cardiovascular and sexual adverse effects, but reports no new clinical results.

This review discusses how the HSD3B1(1245C) genotype may impact androgen physiology and the progression of castration-resistant prostate cancer, and does not report new experimental results.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

This review summarizes recent advancements in steroidal 5α-reductase inhibitors for benign prostatic hyperplasia and reports no new clinical results.

This review discusses recent developments in α1-adrenoceptor antagonists and 5α-reductase inhibitors for treating benign prostatic hyperplasia, reporting no new clinical results while identifying potential areas for future drug development.

This review discusses the development and trials of finasteride for prostate cancer prevention, reporting reduced cancer prevalence but noting concerns about increased high-grade cancer incidence.

This study developed solid lipid nanoparticles for delivering a shRNA-encoding plasmid that effectively reduced 5α-reductase enzyme levels in vitro without significant cytotoxicity, suggesting potential therapeutic applications.

In this study, combining flutamide with finasteride showed additive effects in reducing tumor and prostate growth in a mouse model predictive of androgen-sensitive prostate cancer.

This review highlights that several clinical and epidemiological studies link a diet high in terpenoid compounds with a decreased risk of prostate cancer, supporting the potential use of terpenoids as therapeutic ingredients in treating this disease.

This study on rats found that finasteride and dutasteride increased collagen density in penile tissues and caused changes in prostate cells, but did not significantly alter erectile pressures compared to controls.

This study reports that a novel Nano-Structured Lipid Carrier system for delivering dutasteride may enhance its anticancer effects while reducing systemic side effects in clinical settings.

Early balding may be a sign of future prostate problems.

Low dose finasteride causes only minor changes in PSA levels in men over 50 with BPH.

This study found that some cancer cells exhibit neuronal-like characteristics, which may serve as a mechanism of resistance.

This study found that RADA-PRG hydrogels enhanced skin-derived precursor cell proliferation and improved hair follicle neogenesis in mice, suggesting potential use as a scaffold material in tissue engineering.

This review critically examines the current medical management strategies for BPH/LUTS and reports no new experimental results.

In this study, significantly fewer men treated with finasteride for moderate to severe BPH symptoms experienced acute urinary retention or required subsequent BPH-related surgery compared to placebo-treated patients.

5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.

This study reports that 5-alpha-reductase inhibitors do not prevent prostate cancer and merely reduce the likelihood of undergoing diagnostic biopsies, potentially misleading patients and physicians.

In this case report, treatment with antibiotics, finasteride, and prostate omentalization restored fertility in a 6-year-old German Shepherd with prostatitis and astenoteratozoospermia, avoiding surgical castration.